W
Wakako Maruyama
Researcher at Aichi Gakuin University
Publications - 96
Citations - 5830
Wakako Maruyama is an academic researcher from Aichi Gakuin University. The author has contributed to research in topics: Neuroprotection & Rasagiline. The author has an hindex of 45, co-authored 94 publications receiving 5414 citations. Previous affiliations of Wakako Maruyama include International Institute of Minnesota.
Papers
More filters
Journal ArticleDOI
Mitochondrial Genome Variation in Eastern Asia and the Peopling of Japan
Masashi Tanaka,Vicente M. Cabrera,Ana M. González,José M. Larruga,Takeshi Takeyasu,Takeshi Takeyasu,Noriyuki Fuku,Li Jun Guo,Li Jun Guo,Raita Hirose,Yasunori Fujita,Miyuki Kurata,Ken-ichi Shinoda,Kazuo Umetsu,Yoshiji Yamada,Yoshiji Yamada,Yoshiharu Oshida,Yuzo Sato,Nobutaka Hattori,Yoshikuni Mizuno,Yasumichi Arai,Nobuyoshi Hirose,Shigeo Ohta,Osamu Ogawa,Yasushi Tanaka,Ryuzo Kawamori,Masayo Shamoto-Nagai,Wakako Maruyama,Hiroshi Shimokata,Ryota Suzuki,Hidetoshi Shimodaira +30 more
TL;DR: Population-based comparisons confirmed that present-day Japanese have their closest genetic affinity to northern Asian populations, especially to Koreans, which finding is congruent with the proposed Continental gene flow to Japan after the Yayoi period.
Journal ArticleDOI
Gene therapy for mitochondrial disease by delivering restriction endonuclease SmaI into mitochondria.
Masashi Tanaka,Harm-Jan Borgeld,Jin Zhang,Shin-ichi Muramatsu,Jian-Sheng Gong,Makoto Yoneda,Wakako Maruyama,Makoto Naoi,Tohru Ibi,Ko Sahashi,Masayo Shamoto,Noriyuki Fuku,Miyuki Kurata,Yoshiji Yamada,Kumi Nishizawa,Yukihiro Akao,Nobuko Ohishi,Shigeaki Miyabayashi,Hiraku Umemoto,Tatsuo Muramatsu,Koichi Furukawa,Akihiko Kikuchi,Imaharu Nakano,Keiya Ozawa,Kunio Yagi +24 more
TL;DR: It is demonstrated that mitochondria targeted by the SmaI enzyme showed specific elimination of the mutant mtDNA, resulting in restoration of both the normal intracellular ATP level and normal mitochondrial membrane potential.
Journal ArticleDOI
Rasagiline: Neurodegeneration, neuroprotection, and mitochondrial permeability transition
Moussa B. H. Youdim,Orit Bar Am,Merav Yogev-Falach,Orly Weinreb,Wakako Maruyama,M. Naoi,Tamar Amit +6 more
TL;DR: Development of novel bifunctional anti‐Alzheimer drugs (ladostigil) possessing cholinesterase and brain‐selective MAO inhibitory activity and a similar neuroprotective mechanism of action is led to.
Journal ArticleDOI
Transfection-enforced Bcl-2 overexpression and an anti-Parkinson drug, rasagiline, prevent nuclear accumulation of glyceraldehyde-3-phosphate dehydrogenase induced by an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol.
TL;DR: The results suggest that GAPDH may accumulate in nuclei as a consequence of signal transduction, which is antagonized by anti‐apoptotic Bcl‐2 protein family and rasagiline.
Journal ArticleDOI
Mitochondrial permeability transition mediates apoptosis induced by N-methyl(R)salsolinol, an endogenous neurotoxin, and is inhibited by Bcl-2 and rasagiline, N-propargyl-1(R)-aminoindan.
Yukihiro Akao,Wakako Maruyama,Shigeomi Shimizu,Hong Yi,Yoshihito Nakagawa,Masayo Shamoto-Nagai,Moussa B.H. Youdim,Yoshihide Tsujimoto,Makoto Naoi +8 more
TL;DR: Rasagiline, N‐propargyl‐1(R)‐aminoindan, which is a now under a clinical trial for Parkinson's disease, suppressed the ΔΨm reduction, release of cytochrome c, and apoptosis induced by NM(R),Sal in SH‐SY5Y cells, proving that rasagILine directly targets the mitochondria also.